Asia-Pacific’s medical devices industry saw a drop of 6.67% in deal activity during August 2022, when compared with the last 12-month average, led by Bain Capital’s $3.12bn private equity deal with Evident, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 42 medical devices industry deals worth $3.4bn were announced for the region in August 2022, against the 12-month average of 45 deals.
Of all the deal types, venture financing saw most activity in August 2022 with 37 transactions, representing an 88.1% share for the region.
In second place was M&A with four deals, followed by private equity deals with one transactions, respectively capturing a 9.5% and 2.4% share of the overall deal activity for the month.
In terms of value of deals, private equity was the leading category in Asia-Pacific’s medical devices industry with $3.12bn, while venture financing and M&A deals totalled $212.98m and $15.5m, respectively.
Asia-Pacific medical devices industry deals in August 2022: Top deals
The top five medical devices deals accounted for 97% of the overall value during August 2022.
The combined value of the top five medical devices deals stood at $3.25bn, against the overall value of $3.4bn recorded for the month.
The top five medical devices industry deals of August 2022 tracked by GlobalData were:
1) Bain Capital’s $3.12bn private equity deal with Evident
2) The $52.57m venture financing of CureApp by The Carlyle Group
3) China State-owned Enterprise Structural Adjustment Fund Phase II and Wuxi Guolian Guokang Health Industry Investment Center’s $29.58m venture financing deal with Cygnus Biosciences (Beijing)
4) The $29.19m venture financing of Prismlab China by BASF Venture Capital (Shanghai), Jinyu Bogor Investment Management Co. and Qiming Venture Partners
5) Paragon Care Group Australia’s $15.5m acquisition deal with Specialist Medical Supplies
